FDA Expands CoreValve TAVR Indication to Intermediate-Risk Patients

The expanded indication to include treatment of patients with severe aortic stenosis at intermediate risk for surgery is based on the pivotal SURTAVI data reported this March.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s